Amphastar Pharmaceuticals Net Total Equity Issued/Repurchased 2012-2025 | AMPH
Amphastar Pharmaceuticals net total equity issued/repurchased from 2012 to 2025. Net total equity issued/repurchased can be defined as the sum of all preferred and common equity transactions regarding a company's own stock.
Amphastar Pharmaceuticals Annual Net Total Equity Issued/Repurchased
(Millions of US $) |
| 2024 |
$-90 |
| 2023 |
$-47 |
| 2022 |
$-24 |
| 2021 |
$-13 |
| 2020 |
$-1 |
| 2019 |
$-19 |
| 2018 |
$-16 |
| 2017 |
$-17 |
| 2016 |
$12 |
| 2015 |
$4 |
| 2014 |
$38 |
| 2013 |
$0 |
| 2012 |
$0 |
| 2011 |
$-2 |
| 2009 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.178B |
$0.732B |
|
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
|
